MEDICAMENT DELIVERY FORMULATIONS, DEVICES AND METHODS
Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a propellant and at lease one medicinally active compound, said propellant comprising at least one fluoroolefin having at least two but less than seven carbon atoms.
1 .- 11 . (canceled)
12 . A method of treating a mammal by topical administration comprising topically administering to an area of the mammal needing treatment a formulation comprising at least about 5% by weight of at least one compound of Formula II:
where each R is independently F, or H,
R′ is CF 3 , and
at least one R on the unsaturated terminal carbon is H and at least one of the remaining Rs in Formula II is F.
13 .- 16 . (canceled)
17 . The method of claim 12 wherein said formulation further comprises at least one surfactant selected from the group consisting of C5-C20 fatty alcohols, C5-C20 fatty acids, C5-C20 fatty acid esters, lecithin, glycerides, propyleneglycol esters, polyoxyethanes, polysorbates, sorbitan esters and carbohydrates, or combinations thereof.
18 . The method of claim 12 wherein said at least one compound of Formula II comprises HFO-1234.
19 . The method of claim 18 wherein said HFO-1234 comprises HFO1234yf.
20 . The method of claim 18 wherein said HFO-1234 comprises cisHFO-1234ze.
21 . The method of claim 18 wherein said HFO-1234 comprises transHFO-1234ze.
22 . The method of claim 18 wherein said at least one compound of Formula II is present in the formulation in an amount of about 100%
23 . The method of claim 18 wherein said at least one compound of Formula II is present in the formulation in an amount of from about 5% to about 99% by weight.
24 . The method of claim 18 wherein said at least one compound of Formula II is present in the formulation in an amount of from about 5% to about 95% by weight.
25 . The method of claim 18 wherein said at least one compound of Formula II is present in the formulation in an amount of at least about 50% by weight.
26 . The method of claim 18 wherein said at least one compound of Formula II is present in the formulation in an amount of from about 60% by weight to about 99% by weight.
27 . The method of claim 18 wherein said at least one compound of Formula II consists essentially of HFO-1234.
28 . The method of claim 18 wherein said at least one compound of Formula II has a Global Warming Potential (GWP) of not greater than about 150.
29 . The method of claim 18 wherein said at least one compound of Formula II has a pharmacologically and medicinally acceptable low level of toxicity.
30 . The method of claim 12 wherein said at least one compound of Formula II has a pharmacologically and medicinally acceptable low level of toxicity.
31 . The method of claim 18 wherein said formulation further comprises one or more hydrofluorocarbons.
32 . The method of claim 31 wherein said one or more hydrofluorocarbons comprise pentafluoroethane (HFC-125).
33 . The method of claim 32 wherein said at least one compound of Formula II is present in the formulation in an amount of from about 5% to about 95% by weight.
34 . The method of claim 31 wherein said administering comprises providing a canister containing said formulation under pressure.
35 . The method of claim 31 wherein said canister has a dispensing valve operable between non-dispensing and dispensing positions.